Goldman Sachs Maintains Buy on Karuna Therapeutics, Lowers Price Target to $296
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a 'Buy' rating on Karuna Therapeutics (NASDAQ:KRTX), but lowered the price target from $332 to $296.

November 03, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Karuna Therapeutics but lowered the price target from $332 to $296.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100